Internal Medicine, Hematology & Oncology · San Antonio, TX
NPI
1518168442
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
5206 Research Dr
San Antonio, TX, 78240
Phone (210) 595-5300
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
139,951 services
Medicare patients, 2024
688
Average age 73
Drug cost, 2024
$5.0M
1,484 prescriptions
Company payments, 2025
$114K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John S Renshaw was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 14,610 times for 19 patients. In total John S Renshaw billed 139,951 services in 179 codes, and Medicare paid $2.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 14,610 | 19 | $2.34 | $34K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 11,250 | 41 | $0.11 | $1,240 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 8,700 | 16 | $44.83 | $390K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 8,000 | 12 | $0.06 | $452 |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 6,630 | 11 | $0.26 | $1,747 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 6,309 | 59 | $0.10 | $621 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 5,890 | 20 | $36.81 | $217K |
| J9267 Injection, paclitaxel, 1 mg | Office | 5,404 | 13 | $0.08 | $433 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,348 | 63 | $0.09 | $121 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,060 | 51 | $0.70 | $738 |
| 36415 Venipuncture Blood Collection | Office | 944 | 300 | $8.63 | $8,149 |
| 85025 Blood Count | Office | 827 | 279 | $7.52 | $6,221 |
| 99213 Office E&M - Established | Office | 546 | 301 | $60.69 | $33K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 528 | 14 | $3.60 | $1,898 |
| 80053 Clinical Chemistry | Office | 468 | 147 | $10.25 | $4,798 |
By year: 2022 $1.7M for 165,902 services; 2023 $1.7M for 125,323 services; 2024 $2.0M for 139,951 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 944 | 300 | $8.63 | $8,149 |
| 85025 Blood Count | 827 | 279 | $7.52 | $6,221 |
| 80053 Clinical Chemistry | 468 | 147 | $10.25 | $4,798 |
| 83521 Immunoassay | 232 | 53 | $16.93 | $3,927 |
| 82728 Clinical Chemistry | 167 | 89 | $13.14 | $2,195 |
| 83615 Clinical Chemistry | 153 | 64 | $5.92 | $906 |
| 85007 Blood Count | 135 | 41 | $3.72 | $502 |
| 85027 Blood Count | 135 | 41 | $6.34 | $856 |
| 82784 Immunoassay | 118 | 17 | $9.11 | $1,075 |
| 85055 Blood Count | 102 | 39 | $34.40 | $3,509 |
Medicare prescription drug claims, 2024
In 2024, the drug John S Renshaw prescribed most often to Medicare patients was Xarelto (Rivaroxaban), with 81 prescriptions and refills. In total John S Renshaw wrote 1,484 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | 81 | 193 | 20 | $103K |
| Eliquis Apixaban | 81 | 169 | 23 | $96K |
| Revlimid Lenalidomide | 68 | 68 | Under 11 | $1.0M |
| Jakafi Ruxolitinib Phosphate | 66 | 66 | Under 11 | $1.1M |
| Dexamethasone Generic | 62 | 81 | 22 | $1,064 |
| Hydroxyurea Generic | 53 | 117 | 12 | $1,344 |
| Acyclovir Generic | 53 | 136 | 22 | $918 |
| Anastrozole Generic | 50 | 145 | 17 | $832 |
| Tamoxifen Citrate Generic | 48 | 124 | 14 | $1,132 |
| Gabapentin Generic | 46 | 84 | 13 | $542 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 36 | 58 | Under 11 | $159 |
| Ondansetron Odt Ondansetron | 34 | 35 | 23 | $412 |
| Brukinsa Zanubrutinib | 30 | 30 | Under 11 | $350K |
| Lenalidomide Generic | 28 | 28 | Under 11 | $347K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 27 | 27 | 16 | $853 |
Brand drugs: 505 claims; generic drugs: 979 claims; opioid claims: 72.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John S Renshaw $114K ($114K in general payments such as food, travel and fees) from 12 companies. The largest payer was BeOne Medicines USA, Inc. with $52K.
| Company | Payments | Amount |
|---|---|---|
| BeOne Medicines USA, Inc. ONC | 32 | $52K |
| Abbvie Inc. ABBV | 18 | $21K |
| Janssen Biotech, Inc. JNJ | 5 | $12K |
| BeiGene USA, Inc. ONC | 6 | $11K |
| Karyopharm Therapeutics Inc. KPTI | 8 | $11K |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $5,610 |
| Geron Corporation GERN | 1 | $960 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $125 |
| Pfizer Inc. PFE | 1 | $124 |
| Genzyme Corporation SNY | 1 | $102 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.